Information  X 
Enter a valid email address

Verona Pharma plc (VRP)

  Print      Mail a friend

Thursday 30 November, 2017

Verona Pharma plc

Verona Pharma plc : PDMR Dealing

Verona Pharma plc : PDMR Dealing

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 106.85 pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will have an interest in the Company of 135,787 Ordinary Shares, representing 0.13% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

  
1Details of the person discharging managerial responsibilities/person closely associated
a)NameDavid Ebsworth
2Reason for the notification
a)Position/statusNon-Executive Chairman
b)Initial notification/AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerona Pharma plc
b)LEI213800EVI6O6J3TIAL06
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of 5 pence each
   
 Identification codeGB00BYW2KH80
   
b)Nature of the transactionDavid Ebsworth purchased 10,000 Ordinary Shares
c)Price(s) and volume(s)Price(s)Volume(s)
  106.85 pence per Ordinary Share10,000 Ordinary Shares
   
d)Aggregated informationN/A
   
 -  Aggregated volume 
   
 -  Price 
   
e)Date of the transaction29 November 2017
f)Place of the transactionLondon Stock Exchange, AIM
   

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer[email protected]
  
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
[email protected]
Stewart Wallace / Jonathan Senior / Ben Maddison



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via Globenewswire


a d v e r t i s e m e n t